Physicians Compliance During Maintenance Therapy in Children with Down Syndrome and Acute Lymphoblastic Leukemia.

Abstract 2577 Children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) have an inferior prognosis compared to non-DS ALL patients. We reviewed Methotrexate (MTX)/Mercaptopurine (6MP) maintenance therapy data for children with DS treated according to the NOPHO ALL92 or the NOPHO ALL2000 protocols between 1992 and 2007. The five year event-free survival (pEFS 5y ) for the DS patients was inferior to the non-DS patients (0.50 ± 0.07 vs 0.77 ± 0.01, p st remission at the beginning of maintenance therapy had pEFS 10y below the 522 non-DS control patients (pEFS 10y : 0.58, 95%-CI 0.43–0.77 vs. 0.83, 95%-CI 0.80–0.86, p Disclosures: No relevant conflicts of interest to declare.